The P value in a small trial is generally reflective of the small sample size rather than efficacy. If you combine all the data such as survival, NFL changes and AFS score, you see they all suggest that MPL is slowing disease progression. Add to that the significant improvement gained from the increased dosage enjoyed by cohort 2 and it's hard to prescribe any other reason for the improvements other than that MPL is effective in treating MND/ALS. With consistent data correlation I'd put p value at .001. I may be wrong, it's probably better than that.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-954
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $98.34M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.5¢ | $86.20K | 429.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 67508 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 36444 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |